New pill for opioid addiction heads to first human tests
NCT ID NCT06808932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new oral medication called VK4-116 in 48 healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for opioid dependence and opioid use disorder. Participants will receive a single dose of the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID DEPENDENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences Clinical Kansas
Overland Park, Kansas, 66212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A bold community experiment takes on the opioid crisis
- Can daily text messages help curb opioid cravings and ease chronic pain?
- Could a simple helpline help fight opioid addiction?
- Zapping the brain to beat opioid relapse: new study tests Non-Invasive technique
- New parenting program aims to strengthen bonds for moms battling opioid addiction
- New hope for pain relief without addiction: buprenorphine study